Document is current

Article History

Received: 2 May 2024

Accepted: 16 September 2024

First Online: 28 September 2024

Declarations

:

: The authors declare no competing interests.

: This study adheres to the guidelines set forth in the "Regulations onEthical Review of Human Biomedical Research" (Order No. 11 of theNational Health Commission of the People’s Republic of China) and the "DataSecurity Law of the People’s Republic of China". The breast cancerpathological images utilized in this research have undergone thoroughde-identification. In accordance with relevant regulations, my study does notrequire additional ethical approval and informed consent. The study protocol and the use of de-identified data were reviewed and approved by the Institutional Review Board (IRB) of Hangzhou Danzi University. The IRB determined that the study was exempt from requiring full IRB review because it used existing, de-identified data.

: The study utilized de-identified breast cancer whole-slide images (WSIs) sourced from public datasets. As these data were de-identified and publicly accessible, the requirement for informed consent was waived by the Institutional Review Board (IRB) of Hangzhou Danzi University. This waiver was granted on the basis that the data were already de-identified and did not contain any personal health information. The authors have ensured that all patient data used in this study were handled with confidentiality and privacy. No personal health information was accessed or used in the preparation of this manuscript.